Trial Profile
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Ontamalimab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms CARMEN CD 307
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 06 Apr 2022 This trial has been completed in Portugal(End Date:13-Sep-2021), according to European Clinical Trials Database record.
- 31 Mar 2022 This trial has been completed in Estonia and Italy (End Date:13-Sep-2021), according to European Clinical Trials Database record.
- 03 Mar 2022 Status changed from active, no longer recruiting to discontinued.